US · SERA
Sera Prognostics, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Salt Lake City, UT 84109
- Website
- seraprognostics.com
Price · as of 2024-12-31
$1.91
Market cap 86.17M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $35.80 | +1,774.35% |
| Intrinsic Value(DCF) | $1.90 | -0.52% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $62.92 | +3,194.35% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | $0.00 | $23.17 | |||
| 2021 | $4.11 | $44.71 | $429,741.32 | $0.00 | $0.00 |
| 2022 | $3.95 | $43.60 | $68,231.07 | $0.00 | $0.00 |
| 2023 | $9.53 | $28.54 | $68.02 | $0.00 | $0.00 |
| 2024 | $4.32 | $35.80 | $0.30 | $0.00 | $62.92 |
AI valuation
Our deep-learning model estimates Sera Prognostics, Inc.'s (SERA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $35.80
- Current price
- $1.91
- AI upside
- +1,774.35%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.90
-0.52% upside
Graham-Dodd
—
— upside
Graham Formula
$62.92
+3,194.35% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SERA | Sera Prognostics, Inc. | $1.91 | 86.17M | +1,774% | -1% | — | +3,194% | -4.35 | 3.00 | 1860.23 | -3.05 | — | 3.06 | -6.49% | -47577.92% | -42724.68% | -55.78% | -289.10% | -39.16% | 0.02 | -1308.39 | 1.92 | 1.87 | 0.10 | -1466.00% | -7484.00% | -4403.00% | -10.67% | -0.57 | -120.66% | 0.00% | 0.00% | 0.82% | -2.67 | -6.40 | 1270.67 | -3.22 |
| APYX | Apyx Medical Corporation | $3.27 | 134.17M | +662% | -86% | — | — | -1.69 | 2.80 | 0.83 | -2.79 | -7.60 | 2.80 | 61.04% | -39.18% | -48.78% | -115.17% | -88.10% | -32.70% | 2.73 | -3.19 | 5.26 | 4.40 | -0.42 | 2222.00% | -811.00% | 22461.00% | -47.15% | -1.68 | -87.74% | 0.00% | 0.00% | 0.00% | -2.49 | -2.50 | 0.97 | -0.58 |
| ATOS | Atossa Therapeutics, Inc. | $4.43 | 38.15M | — | — | — | — | -3.65 | 1.30 | — | -0.80 | — | 1.30 | 0.00% | — | — | -31.39% | -1873.25% | -29.54% | 0.00 | — | 14.99 | 14.31 | 2.58 | -1667.00% | — | 45.00% | -22.60% | -4.23 | -1427.53% | 0.00% | 0.00% | 0.00% | -0.80 | -1.05 | — | 7.27 |
| CGTX | Cognition Therapeutics, I… | $1.09 | 80.2M | — | — | — | — | -0.50 | 0.91 | — | 0.21 | — | 0.91 | 0.00% | — | — | -157.19% | 1117.89% | -103.89% | 0.04 | -2158.64 | 2.65 | 2.49 | 0.72 | -116.00% | — | 7617.00% | -167.08% | -2.56 | 589.91% | 0.00% | 0.00% | 0.00% | 0.13 | 0.25 | — | -12.38 |
| HURA | TuHURA Biosciences, Inc. | $1.67 | 94.32M | — | — | — | — | -1.80 | 2.67 | — | -1.52 | — | 2.67 | 0.00% | — | — | -332.67% | 4773.62% | -178.25% | 0.01 | -4.26 | 3.68 | 2.42 | 0.71 | -8925.00% | — | 2291.00% | -37.91% | -2.76 | 3999.15% | 0.00% | 0.00% | 28.55% | -1.50 | -1.80 | — | -5.49 |
| LUCD | Lucid Diagnostics Inc. | $1.44 | 146.54M | +85,309% | -60% | — | — | -1.54 | 13.02 | 16.16 | -1.56 | — | 15.08 | -90.20% | -1059.64% | -1047.61% | -2956.43% | 5531.77% | -157.04% | 3.94 | -1771.23 | 1.07 | 0.97 | 0.02 | -1667.00% | 7900.00% | 3556.00% | -63.78% | -1.88 | 5379.70% | 0.00% | 0.00% | 0.00% | -1.50 | -1.54 | 15.90 | -12.37 |
| ONCY | Oncolytics Biotech Inc. | $1.13 | 113.41M | — | — | — | — | -2.33 | 12.32 | — | -1.69 | — | 12.32 | 0.00% | — | — | -189.05% | 442.22% | -107.48% | 0.18 | — | 2.82 | 2.39 | 0.43 | 0.00% | — | -440.00% | -36.90% | -4.03 | 343.91% | 0.00% | 0.00% | 0.00% | -1.68 | -2.16 | — | -35.01 |
| RPID | Rapid Micro Biosystems, I… | $4.33 | 191.92M | +463% | -78% | — | — | -2.22 | 1.38 | 3.71 | -1.28 | — | 1.38 | -0.39% | -177.96% | -167.16% | -48.50% | -155.83% | -38.81% | 0.08 | — | 4.61 | 3.32 | 0.23 | -1148.00% | 2457.00% | -300.00% | -43.71% | -2.51 | -142.09% | 0.00% | 0.00% | 0.00% | -1.19 | -1.31 | 2.12 | -4.66 |
| SRZN | Surrozen, Inc. | $27.80 | 238.29M | — | -83% | — | — | -0.55 | -1.64 | 3.28 | -0.37 | -34.54 | -1.64 | 100.00% | -239.69% | -596.56% | -767.91% | 121.02% | -134.46% | -0.40 | — | 5.32 | 5.07 | 1.08 | 159.00% | — | -5669.00% | -50.45% | -2.41 | 83.66% | 0.00% | 0.00% | 0.00% | -0.35 | -0.50 | 0.84 | -8.68 |
| STSS | Sharps Technology, Inc. | $1.73 | 50.16M | — | — | — | — | -0.04 | 0.19 | — | -0.48 | -0.01 | 0.19 | 0.00% | — | — | -187.23% | -159.55% | -97.33% | 1.89 | -4.61 | 0.61 | 0.19 | -0.42 | 78195.00% | — | -2322.00% | -1894.69% | -1.34 | -144.00% | 0.00% | 0.00% | 0.00% | -0.42 | -0.46 | — | -10.43 |
| TVGN | Tevogen Bio Holdings Inc. | $0.26 | 53.24M | — | — | — | — | -12.18 | -25.05 | — | -12.85 | -0.05 | -25.05 | 0.00% | — | — | 27.16% | 2087.12% | -306.17% | -0.43 | -291.05 | 0.26 | 0.16 | -0.12 | 2330000.00% | — | 4449.00% | -7.18% | -1.33 | 467.53% | 0.00% | 0.00% | 55.48% | -3.15 | -14.07 | — | -89.34 |
About Sera Prognostics, Inc.
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
- CEO
- Zhenya Lindgardt
- Employees
- 63
- Beta
- 0.99
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.90 ÷ $1.91) − 1 = -0.52% (DCF, example).